[1] Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence and outcomes. Hepatology,2016,64(1):73-84. [2] Loomba R,Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol,2013,10(11):686-690. [3] 曾民德. 非酒精性脂肪性肝病:回顾历史,展望未来. 实用肝脏病杂志,2016,19(2):129-131. [4] Volta U,Bonazzi C,Bianchi FB,et al. IgA antibodies to dietary antigens in liver cirrhosis. Ric Clin Lab,1987,17(3):235-242. [5] Tilg H,Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease:the multiple parallel hits hypothesis. Hepatology,2010,52(5):1836-1846. [6] Henao-Mejia J,Elinav E,Jin C,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature,2012,482(7384):179-185. [7] Steinbakk M,Naess-Andresen CF,Lingaas E,et al. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet,1990,336(8718):763-765. [8] Vermeire S,Van Assche G,Rutgeerts P. Laboratory markers in IBD:useful,magic,or unnecessary toys. Gut,2006,55(3):426-431. [9] D'incà R,Dal Pont E,Di Leo V,et al. Can calprotectin predict relapse risk in inflammatory bowel disease&quest. Am J Gastroenterol,2008,103(8):2007-2014. [10] Kolho KL,Korpela K,Jaakkola T,et al. Fecal microbiota in pediatric inflammatory bowel disease and its relation to inflammation. Am J Gastroenterol,2015,110(6):921-930. [11] Montalto M,Gallo A,Santoro L,et al. Role of fecal calprotectin in gastrointestinal disorders. Eur Rev Med Pharmacol Sci,2013,17(12):1569-1582. [12] D'Haens G,Ferrante M,Vermeire S,et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis,2012,18(12):2218-2224. [13] Gundling F,Schmidtler F,Hapfelmeier A,et al. Fecal calprotectin is a useful screening parameter for hepatic encephalopathy and spontaneous bacterial peritonitis in cirrhosis. Liver Int,2011,31(9):1406-1415. [14] Alempijevic T,Stulic M,Popovic D,et al. The role of fecal calprotectin in assessment of hepatic encephalopathy in patients with liver cirrhosis. Acta Gastroenterol Belg,2014,77(3):302-305. [15] Marie I,Leroi AM,Menard JF,et al. Fecal calprotectin in systemic sclerosis and review of the literature. Autoimmun Rev,2015,14(6):547-554. [16] Pendyala S,Neff LM,Suárez-Farinas M,et al. Diet-induced weight loss reduces colorectal inflammation:implications for colorectal carcinogenesis. Am J Clin Nutr,2011,93(2):234-242. [17] Hardy T,Oakley F,Anstee QM,et al. Nonalcoholic fatty liver disease:Pathogenesis and disease spectrum. Annu Rev Pathol,2016,11(1):451-496. [18] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南. 实用肝脏病杂志,2007,10(1):1-3. [19] Coorevits L,Baert FJ,Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med,2013,51(4): 825-831. [20] Mehal WZ. The gut-liver axis:A busy two-way street. Hepatology,2012,55(6):1647-1649. [21] Miele L,Valenza V,La Torre G,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49(6):1877-1887. [22] Giorgio V,Miele L,Principessa L,et al. Intestinal permeability is increased in children with non-alcoholic fatty liver disease,and correlates with liver disease severity. Dig Liver Dis,2014,46(6):556-560. [23] Gabele E,Dostert K,Hofmann C,et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55(6): 1391-1399. [24] Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology,2015,149(5):1275-1285. [25] Yamamoto T,Shiraki M,Bamba T,et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis,2014,29(4):485-491. |